Ten year follow-up of healthy children who received one or two injections of varicella vaccine

Pediatric Research

Volumn 23, Issue 2, 2004, Pages 132-137

  Kuter, Barbara ^a   Matthews, Holly ^a   Shinefield, Henry ^b   Black, Steve ^b   Dennehy, Penelope ^c   Watson, Barbara ^d,f   Reisinger, Keith ^e   Kim, Lee Lian ^a   Lupinacci, Lisa ^a   Hartzel, Jonathan ^a   Chan, Ivan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b KAISER PERMANENTE   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d ALBERT EINSTEIN MEDICAL CENTER   (United States)

^e Primary Physicians Research   (United States)

^f Philadelphia Fire Department   (United States)

Author keywords

Persistence of antibody; Vaccine efficacy; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INCIDENCE; INFANT; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NORMAL HUMAN; PHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX RATIO; TIME; VACCINATION; VARICELLA ZOSTER VIRUS;

AGE DISTRIBUTION; ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MALE; PROBABILITY; RISK ASSESSMENT; SEX DISTRIBUTION; TIME FACTORS; VACCINATION; VACCINES, ATTENUATED;

EID: 10744231582     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1097/01.inf.0000109287.97518.67     Document Type: Article

References (36)

1. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for the use of live attenuated varicella vaccine. Pediatrics 1995; 95: 791-6.
2. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45(RR-11).
3. Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 1996; 15: 49-54.
4. Kuter BJ, Weibel RE, Guess HA, et al. Oka Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9: 643-7.
5. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310: 1409-15.
6. Izurieta HS, Strebel PM, Blake, PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278: 1495-9.
7. Clements DA, Armstrong CB, Ursano AM, Moggio NM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995; 14: 874-9.
8. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 1997; 100: 761-6.
9. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287: 606-11.
10. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11: 19-23.
11. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX®) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87: 604-10.
12. Bernstein HH, Rothstein EP, Watson BM, et al. Clinical survey of natural varicella (nv) compared with breakthrough varicella (bv) after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993; 92: 833-7.
13. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91: 17-22.
14. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32: 189-93.
15. Krah DL. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am 1996; 10: 507-27.
16. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9: 111-16.
17. LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg S, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992; 66: 1016-20.
18. LaRussa P, Steinberg S, Sharrar R, Galea S, Gershon A: Identification, differentiation of wild (WT)-, vaccine (OKA)-strain VZV isolates by PCR from recipients of live attenuated varicella vaccine (LAVV) [Abstract P-49]. Presented at the 3rd International Conference on the Varicella-Zoster Virus, Palm Beach, FL, March 10, 1997.
19. Vessey SR, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr 2001; 139: 297-304.
20. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
21. Johnson NL, Kotz S, Kemp AW. Univariate discrete distributions, 2nd ed. New York: Wiley, 1992.
22. Chan ISF, Li S, Matthews H, et al. Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med 2002; 21: 3411-30.
23. Ross AH. Modification of chickenpox in family contacts by administration of gamma globulin. N Engl J Med 1962; 267: 369-76.
24. Lachin JM. Biostatistical methods: the assessment of relative risk. New York: Wiley, 2000.
25. Li S, Chan ISF, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J, 2002; 21: 337-42.
26. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000; 6: 451-4.
27. Seward J, Jumaan A, Schmid S. Varicella vaccine revisited [Letter]. Nat Med 2000; 6: 1298-9.
28. LaRussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA. Varicella vaccine revisited [Letter]. Nat Med 2000; 6: 1299.
29. CDC. National, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, 2001. MMWR 2002; 51: 664-6.
30. Arvin AM. Varicella-zoster virus. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields’ virology. 3rd ed. Philadelphia: Lippencott-Raven, 1996: 2547-85.
31. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune response in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995; 20: 316-9.
32. Zerboni L, Nader S, Aoki K, Arvin A. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 1998; 177: 1701-4.
33. Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 1995; 172: 217-9.
34. American Academy of Pediatrics. Varicella zoster infections. In: 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997: 573-85.
35. Advisory Committee on Immunization Practices. Measles, mumps and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. MMWR 1998; 47(RR-8).
36. National Advisory Committee on Immunization. Canadian Immunization Guide. 6th ed. Ottawa, Canada: Department of National Health and Welfare, Ministry of Supply and Services, 2002:Catalog No. H49-8/2002E.